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Abstract
Background: The genetic mechanisms for families who meet the clinical criteria for Lynch syndrome (LS) but do
not carry pathogenic variants in the mismatch repair (MMR) genes are still undetermined. We aimed to study the
potential contribution of genes other than MMR genes to the biological and clinical characteristics of Norwegian
families fulfilling Amsterdam (AMS) criteria or revised Bethesda guidelines.
Methods: The Hereditary Cancer Biobank of the Norwegian Radium Hospital was interrogated to identify
individuals with a high risk of developing colorectal cancer (CRC) for whom no pathogenic variants in MMR
genes had been found in routine diagnostic DNA sequencing. Forty-four cancer susceptibility genes were
selected and analyzed by using our in-house designed TruSeq amplicon-based assay for targeted sequencing.
RNA splicing- and protein-dedicated in silico analyses were performed for all variants of unknown significance
(VUS). Variants predicted as likely to affect splicing were experimentally analyzed by resorting to minigene
assays.
Results: We identified a patient who met the revised Bethesda guidelines and carried a likely pathogenic
variant in CHEK2 (c.470 T > C, p.I157T). In addition, 25 unique VUS were identified in 18 individuals, of which 2
exonic variants (MAP3K1 c.764A > G and NOTCH3 c.5854G >A) were analyzed in the minigene splicing assay
and found not to have an effect on RNA splicing.
Conclusions: Among high-risk CRC patients that fulfill the AMS criteria or revised Bethesda guidelines, targeted gene
sequencing identified likely pathogenic variant and VUS in other genes than the MMR genes (CHEK2, NOTCH3 and
MAP3K1). Our study suggests that the analysis of genes currently excluded from routine molecular diagnostic screens
may confer cancer susceptibility.
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Background
Heredity represents a major cause of colorectal cancer
(CRC) with at least 20% of the cases estimated to de-
velop due to genetic factors and about 5% being linked
to inherited variants in cancer-predisposing genes [1–4].
Currently, patients with CRC are referred to germline
mismatch repair (MMR) testing based on the identifica-
tion of high-risk phenotypic features (i.e. early age of on-
set, family history, clinical criteria), but beyond
microsatellite instability (MSI) and MMR
immunohistochemistry (IHC) testing for Lynch syn-
drome (LS), no systematic approach to hereditary risk
assessment exists [5].
LS is caused by a defective MMR system due to pres-
ence of germline defects in at least one of the MMR
genes, MLH1, MSH2, MSH6, PMS2 or to deletions of
the 3′ portion of the EPCAM gene [6]. LS is clinically
classified according to the Amsterdam (AMS) criteria
and/or the Bethesda guidelines, both relying in clinical
information and family history. The Bethesda guidelines
also take into account the MSI signature characteristic
of MMR-deficient tumors [7–10]. LS patients have an
increased lifetime risk of CRC (70–80%), endometrial
cancer (50–60%), stomach cancer (13–19%), ovarian
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cancer (9–14%), cancers of the small intestine, the biliary
tract and brain as well as carcinoma of the ureters and
renal pelvis [11].
However, a high proportion of cases who meet the
clinical criteria for LS (~ 60%) do not carry patho-
genic variants in the MMR genes and have been re-
ported as familial colorectal cancer type X (FCCTX)
or Lynch-like syndrome (LLS) according to their MSI
status [12–16]. The genetic mechanisms are undeter-
mined in the majority of these families [14].
DNA sequencing (DNA-seq) studies using multi-
gene panels have reported that as much as ~ 18% of
patients diagnosed with CRC below the age of 50 years
have pathogenic variants in several genes that are not
traditionally associated with CRC (ATM, CHEK2,
BRCA1, BRCA2, CDKN2A and PALB2) [5, 17]. Not-
ably, there is a need to determine whether these vari-
ants contribute to hereditary CRC risk via the
combination of low- and moderate-penetrance suscep-
tibility alleles [5, 17, 18].
Given the high frequency and wide spectrum of
pathogenic variants, it has been suggested that gen-
etic counseling and testing with a multigene panel
should be considered for all patients with early-onset
CRC [17, 19–23]. Importantly, the identification of
high-risk CRC patients is a major issue, because
morbidity and mortality from CRC and extracolonic
cancers in these patients and their relatives can be
decreased by early screening and intensive surveil-
lance [19, 24–26].
In an effort to discover inherited genetic variants
that influence biological and clinical characteristics of
familial CRC developed in unrelated high-risk pa-
tients, who previously tested negative for pathogenic
variants in MMR genes, we examined 44 cancer asso-
ciated genes using next generation sequencing (NGS),
and applied minigene-based assay to analyze the im-
pact of a subset of genetic variants on RNA splicing.
Methods
Study population
The Hereditary Cancer Biobank of the Norwegian Ra-
dium Hospital was used to identify unrelated high-risk
CRC individuals from families that fulfilled the AMS cri-
teria or the revised Bethesda guidelines [7–10, 27]. By
the standard diagnostic clinical techniques, all study sub-
jects were demonstrated not to carry pathogenic variants
or large genomic rearrangements in MMR genes
(MLH1, MSH2, MSH6 or PMS2).
Ethical approval for the study was granted by the Nor-
wegian Data Inspectorate and Ethical Review Board (ref
2015/2382). All examined patients signed an informed
consent for their participation in the study.
Targeted sequencing
Genomic DNA was isolated from peripheral blood sam-
ples and targeted sequencing was carried out using a
TrueSeq amplicon based assay v.1.5 on a MiSeq appar-
atus, as previously described [28, 29]. The 44-gene panel
used in this study includes genes associated with cancer
predisposition as described in a prior study [28, 29].
Sequencing data analysis
Paired-end sequence reads were aligned to the human
reference genome (build GRCh37) using the BWA-mem
algorithm (v.0.7.8-r55) [30]. The initial sequence align-
ments were converted to BAM format and subsequently
sorted and indexed with SAMtools (v.1.1) [30]. Genotyp-
ing of single nucleotide variants (SNV) and short indels
was performed by GATK’s HaplotypeCaller. Filtering of
raw genotype calls and assessment of callable regions/
loci were done according to GATK’s best practice proce-
dures, as described more detailed previously [28].
Variants were annotated using ANNOVAR (version
November 2015) [31] and were queried against a range
of variant databases and protein resources, namely
dbSNP (build 147) [32], 1000 Genome Project phase3
[33], Exome Aggregation Consortium (ExAC) (http://
exac.broadinstitute.org, accessed August 2015) [34],
Genome Aggregation Database (gnomAD) (http://gno-
mad.broadinstitute.org, accessed October 2017) [34],
Norwegian Germline Variations Database (http://norgen-
e.no/vcf-miner/, accessed October 2017), ClinVar (May
2016) [35], UniProt Knowledgebase (release March
2016) [36] and the Pfam protein domain database (v29,
December 2015) [28, 37].
Nomenclature and classification of genetic variants
The nomenclature guidelines of the Human Genome
Variation Society (HGVS) were used to describe the de-
tected genetic variants [38]. The recurrence of the iden-
tified variants was established by interrogating four
databases (in their latest releases as of November 2016):
the Leiden Open Variation Database (LOVD), the Uni-
versal Mutation Database (UMD), ClinVar and the Hu-
man Gene Mutation Database (HGMD). The variants
were classified according to the 5-tier classification sys-
tem into the following categories: class 5 (pathogenic),
class 4 (likely pathogenic), class 3 (uncertain variants or
variants of unknown significance, VUS), class 2 (likely
not pathogenic) and class 1 (not pathogenic) [3].
In silico analyses of VUS
Two types of bioinformatics methods were used to pre-
dict the impact of selected variants on RNA splicing.
First, we used MaxEntScan (MES) and SSF-like (SSFL)
to predict variant-induced alterations in 3′ and 5′ splice
site strength, as described by Houdayer et al. 2012 [39],
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except that here both algorithms were interrogated by
using the integrated software tool Alamut Batch version
1.5, (Interactive Biosoftware, http://www.interactive-bio-
software.com). For prediction of variant-induced impact
on exonic splicing regulatory elements (ESR), we
resorted to ΔtESRseq- [40], ΔHZei- [41], and SPANR-
based [42] as described by Soukarieh et al. [43]. Score
differences (Δ) between variant and wild-type (WT)
cases were taken as proxies for assessing the probability
of a splicing defect. More precisely, we considered that a
variant mapping at a splice site was susceptible of nega-
tively impacting exon inclusion if ΔMES≥15% and
ΔSSFL≥5% [39], whereas an exonic variant located out-
side the splice sites was considered as a probable inducer
of exon skipping if negative Δ scores (below the thresh-
olds described below) were provided by all the 3 ESR-
dedicated in silico tools. We chose the following thresh-
olds: <− 0.5 for ΔtESRseq-, <− 10 for ΔHZei-, and < −
0.5 for SPANR-based scores. In addition, we evaluated
the possibility of variant-induced de novo splice sites by
taking into consideration local changes in MES and
SSFL scores. In this case, we considered that variants lo-
cated outside the splice sites were susceptible of creating
a competing splice site if local MES scores were equal to
or greater than those of the corresponding reference
splice site for the same exon.
In silico protein impact predictions of missense vari-
ants were performed with Align-GVGD (the VUS were
predicted as deleterious when the values were from C35
or higher), SIFT, and MAPP using Alamut Batch version
1.4.4 (Interactive Biosoftware) and additionally with
PolyPhen-2 and MutationTaster [44–48].
Cell-based minigene splicing assays
In order to determine the impact of selected exonic vari-
ants on splicing, we performed functional assays based
on the comparative analysis of the splicing pattern of
WT and mutant reporter minigenes, as follows. First,
genomic regions containing the exon of interest (internal
exons only) and at least 150 nucleotides of the flanking
introns were amplified by PCR [49] using patients’ DNA
as template and primers indicated in Additional file 1:
Table S1. Next, representative minigenes were created
by inserting the PCR-amplified fragments into a previ-
ously linearized pCAS2 vector [43]. All constructs were
sequenced to ensure that no unwanted mutations had
been introduced into the inserted fragments during PCR
or cloning. Then, WT and mutant minigenes were trans-
fected into HeLa cells grown in 12-well plates (at ~ 70%
confluence) using the FuGENE 6 transfection reagent
(Roche Applied Science). Twenty-four hours later, total
RNA was extracted using the NucleoSpin RNA II kit
(Macherey Nagel) and, the minigenes’ transcripts were
analyzed by semi-quantitative RT-PCR using the
OneStep RT-PCR kit (Qiagen), as previously described
[43]. The sequences of the RT-PCR primers are shown
in Additional file 1: Table S1. Later, RT-PCR products
were separated by electrophoresis on 2.5% agarose gel
containing EtBr and visualized by exposure to UV light
under saturating conditions using the Gel Doc XR image
acquisition system (Bio-Rad), followed by gel-
purification and Sanger sequencing for proper identifica-
tion of the minigenes’ transcripts. Finally, splicing events
were quantitated by performing equivalent fluorescent
RT-PCR reactions followed by capillary electrophoresis
on an automated sequencer (Applied Biosystems), and
computational analysis by using the GeneMapper v5.0
software (Applied Biosystems).
Results
Clinical characteristics and family history
Upon querying the Hereditary Cancer Biobank of the
Norwegian Radium Hospital for cases that fulfill the
AMS and/or the revised Bethesda guidelines, we identi-
fied 34 unrelated potential high-risk CRC individuals
who did not carry pathogenic variants in MMR genes.
The median age at first CRC diagnosis was 51.5 years
(range: 34–86 years).
Pedigree information showed that 13 (38%) families
fulfilled the AMS I and/or II criteria and the revised Be-
thesda guidelines while 21 (62%) met the revised Be-
thesda guidelines only (Table 1). Fifteen (44%) patients
had tumors with MSI and/or MMR IHC data available,
of which 2 (13%) were MSI-high and/or MMR deficient.
Clinical, family and tumor data information is detailed
in Table 1.
Germline findings
Given that the families that fulfilled the AMS criteria
and/or the Bethesda guidelines did not carry pathogenic
variants in the MMR genes, we hypothesized that other
genes could be implicated in the genetic determinism of
these phenotypes.
In order to pursue this hypothesis, we collected DNA
samples from all probands and performed high-
throughput sequencing of a panel of 44 cancer-
associated genes. For the 34 samples, mean depth of
coverage ranged from 127 to 507 with the fraction of
target bases with coverage ≥25 ranging from 80% to 93.
The NGS results revealed that each individual carried an
average of 26 SNV (between 19 and 33 per individual) in
the set of 44 cancer susceptibility genes, most of which
were common polymorphisms (allele frequency ≥ 1% in
the general population) according to the ExAC database,
and some being classified as benign or likely benign
(class 1 or class 2) according to either ClinVar or the
American College of Medical Genetics and Genomics
(ACMG) guidelines [35, 50] (Table 2).
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Importantly, we identified a likely pathogenic variant
in a moderate-penetrance gene (CHEK2 c.470 T > C,
p.I157T) in a female patient diagnosed with colon cancer
at 42 years, melanoma at 44 years and BC at 57 years
with a proficient IHC MMR profile and fulfilling the re-
vised Bethesda guidelines (Patient 19,609) (Table 1).
The CHEK2 c.470 T > C has been classified as patho-
genic according to the ACMG guidelines [51], and has a
lower allele frequency (1.89*10–3) in the Norwegian
population, compared to the non-Finnish European
population (5.4*10–3) (http://norgene.no/vcf-miner/ and
gnomAD database, respectively) [34, 35, 50]. The variant
Table 1 Summary of International Classification of Diseases, 9th Revision (ICD9), gender, age at diagnosis, clinical criteria and tumor
molecular characteristics of the familial CRC families
Patient_ID Gender ICD9 diagnosis (age) AMS criteria Revised Bethesda Tumor molecular characteristics
3222 F CC (54), Hyperplastic polyp (55/61/62/63/65), BC (70) 0 Y MMR IHC proficient
3308 F CC (43), BC (51/52) 0 Y MMR IHC proficient
3387 F BC (40), OC (70), CC (80) 0 Y MMR IHC proficient
3426 M MM (39) I & II Y na
4932 F CC (34), EC (40), Hyperplastic polyp (43), BT (46) I & II Y na
5324 F M (52), CC (59), SMC (na), BC (72) 0 Y na
6174 F Hyperplastic polyp (63/67), BC (65) I & II Y MMR IHC proficient
6977 F TC (66) 0 Y MMR IHC proficient
9876 F M (45), BC (54) 0 Y na
9998 F Hyperplastic polyp (45), CC (45) II Y MMR IHC proficient
10,675 F BC (51), Hyperplastic polyp (59), TC (60) II Y na
12,954 F Hyperplastic polyp (69), ML (70) II Y na
13,072 M Hyperplastic polyp (63/64/65), CC (65/67) 0 Y na
14,930 F Hyperplastic polyp (86), CC (86) 0 Y MMR IHC proficient
18,843 F BC (44), CC (49), SMC (na) 0 Y na
19,411 M PC (70) 0 Y MSH6 IHC deficient
19,673 F BC (40/42) II Y na
20,612 F Hyperplastic polyp (59/65), EC (70) 0 Y na
21,368 F OC (62) 0 Y na
22,295 F Hyperplastic polyp (53), M (58) 0 Y na
23,761 F Hyperplastic polyp (40/42/44), BC (50) 0 Y na
23,910 F M (43), Hyperplastic polyp (49), BC (63), BT (63) 0 Y na
24,140 F CC (45/67), BC (56) 0 Y na
24,447 F BC (57/66), CC (66) 0 Y MLH1/PMS2 IHC deficient and MSI
11,705 F THC (53), KC (53/63) II Y MMR IHC proficient
12,673 F OC (23), SMC (36), RC (62) II Y na
13,393 M RC (48), CST (58) I & II Y MMR IHC proficient and MSS
14,963 F Hyperplastic polyp (69), BC (62) 0 Y na
19609a F CC (42), M (44), BC (57) 0 Y MMR IHC proficient
22,953 F BC (53) II Y na
24,789 F CC (43), RC (65), BC (72) I & II Y MMR IHC proficient and MSS
25,167 M CC (55) I & II Y MMR IHC proficient
5597 M Hyperplastic polyp (53/54), SC (55), KC (62) 0 Y MMR IHC proficient
8913 F Hyperplastic polyp (59), BC (61), TC (69) 0 Y na
CRC colorectal, ICD9 diagnosis International Classification of Diseases, 9th Revision, CC colon cancer, BC breast cancer, AMS Amsterdam criteria, 0 not fulfill the AMS
criteria, Y yes, MMR mismatch repair, IHC immunohistochemistry, MSI microsatellite instabily, MSS microsatellite stable, na not available, OC ovary cancer, MM
multiple myeloma, EC endometrial cancer, BT brain tumor, M melanoma, SMC other malignant of the skin, TC trachea, bronchus, lung cancer, ML malignant
neoplasms of lymphoid, PC prostate cancer, THC thyroid cancer, KC kidney cancer, RC rectum cancer, CST malignant neoplasm of connective and soft tissue, SC
stomach cancer
a Patient carrying CHEK2 c.470 T > C, p.I157T
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
3222 NOTCH3
NM_000435:
c.5854G >A,
p.V1952 M
(rs115582213)b
POLE NM_006231:
c.3046G > A,
p.V1016 M
(rs147692158)
ATM NM_000051:
c.5071A > C,
p.S1691R
(rs1800059)
BRCA1 NM_007300:
c.5019G > A,
p.M1673I
(rs1799967)
PALB2 NM_024675:
c.2993G > A,
p.G998E
(rs45551636)
PALB2 NM_024675:
c.2014G > C,
p.E672Q
(rs45532440)
rs459552, rs659243,
rs2240308, rs1799966,
rs16942, rs16941,
rs169547, rs4986764,
rs1805107, rs506504,
rs832582,
rs5868032, rs1042821,
rs3219484, rs1044009,
rs152451, rs2228006,
rs1805321, rs4796033,
rs1042522, rs861539,
rs13125836
28
3308 NBN NM_002485:
c.1720 T > A, p.L574I
(rs142334798)POLE
NM_006231:
c.4523G > A,
p.R1508H
(rs142508245)
BARD1N M_000465:
c.1075_1095del,
p.L359-P365delLPECSSP
(rs28997575)
rs459552, rs659243,
rs11528010, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs702689, rs832582,
rs5868032, rs1799977,
rs1042821, rs3219484,
rs1805794, rs1044009,
rs2228006, rs5744934,
rs5744751, rs4796033,
rs1042522
24
3387 na CDKN2A
N M_000077:
c.442G > A,
p.A148T
(rs3731249)
rs459552, rs659243,
rs1801516, rs2240308
rs2070094, rs2229571,
rs11528010, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs702689,
rs832582, rs5868032,
rs3219489, rs1044009,
rs2228006, rs1805321,
rs5744934, rs1042522
23
3426 na na rs459552, rs659243,
rs1801516, rs2240308,
rs2070094, rs2229571,
rs1048108, rs11528010,
rs144848, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs702689, rs832582,
rs5868032, rs1805794,
rs1044009, rs2228006,
rs1805321, rs1042522,
rs13125836
23
4932 NOTCH3
NM_000435:
c.5854G >A,
p.V1952 M
(rs115582213)a
STK11
NM_00045:c.841C >
A, p.P281T
(rs377208033)
na rs459552, rs659243,
rs1801516, rs2240308,
rs2229571, rs11528010,
rs1799966, rs16942,
rs16941, rs799917,
rs144848, rs169547,
rs1805107, rs506504,
rs12642536, rs702689,
rs832582, rs5868032,
rs3219489, rs1805794,
rs1044009, rs2228006,
rs1805321, rs861539
26
5324 na na 19
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals (Continued)
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs12642536,
rs832582, rs1799977,
rs3219489, rs1044009,
rs2228006, rs1805321,
rs5744934
6174 na PMS2 NM_000535:
c.1454C > A, p.T485
K (rs1805323)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1048108,
rs1799966, rs16942,
rs16941, rs799917,
rs4986850, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs12642536, rs702689,
rs832582, rs5868032,
rs1799977, rs3219484,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs1042522, rs861539
29
6977 na BARD1 NM_000465:
c.1075_1095del, p.L359-
P365delLPECSSP
(rs28997575) BARD1
NM_000465: c.1972C >
T, p.R658C
(rs3738888)
BRCA2 NM_000059:
c.9976A > T, p.K3326X
(rs11571833)
rs459552, rs659243,
rs1801516, rs2240308,
rs1799966, rs16942,
rs16941, rs799917,
rs144848, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs12642536, rs702689,
rs832582, rs3219489,
rs1044009, rs2228006,
rs5744934, rs1042522,
rs861539, rs28908468
27
9876 PSMC3IP NM_016556:
c.136G > A, p.V46 M
(rs757057684) RAD51B
NM_133509: c.1063G > A,
p.A355T (rs61758785)
RAD51D NM_002878:
c.698A > G, p.E233G
(rs28363284)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs169547,
rs4986764, rs1805107,
rs506504, rs702689,
rs832582, rs5868032,
rs1799977, rs1042821,
rs1805794, rs1044009,
rs2228006, rs1726801
21
9998 na MSH6 NM_000179:
c.2633 T > C,
p.V878A
(rs2020912)
rs459552, rs659243,
rs1801516, rs2240308,
rs2070094, rs2229571,
rs1048108, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs12642536,
rs702689, rs832582,
rs5868032, rs1799977,
rs1044009, rs2228006,
rs1805321, rs5744751,
rs1042522
24
10,675 na PMS2 NM_000535:
c.1531A > G,
p.T511A
(rs2228007)
rs459552, rs659243,
rs1801516, rs2070094,
rs2229571, rs11528010,
rs1799966, rs16942,
rs16941rs799917,
rs144848, rs169547,
26
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals (Continued)
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
rs4986764, rs1805107,
rs506504, rs1126497,
rs702689, rs832582,
rs5868032, rs1799977,
rs1805794, rs1044009,
rs2228006, rs10254120,
rs1042522
12,954 MUTYH NM_012222:
c.812G > A,
p.R271Q
(rs149866955)
RAD51C NM_058216:
c.790G > A, p.G264S
(rs147241704)
PMS2 NM_000535:
c.1789A > T, p.T597S
(rs1805318)
rs459552, rs659243,
rs2240308, rs2229571,
rs144848, rs169547,
rs4986764, rs1805107,
rs506504, rs12642536,
rs702689, rs832582,
rs5868032, rs1044009,
rs2228006, rs1805321,
rs1726801, rs4796033,
rs1042522
22
13,072 BRCA1 NM_007300:
c.4315C > T, p.L1439F
(rs781260818)
PMS2 NM_000535:
c.1531A > G, p.T511A
(rs2228007)
rs459552, rs659243,
rs1801516, rs2240308,
rs2070094, rs2229571,
rs11528010, rs1799966,
rs16942, rs16941,
rs799917, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs12642536,
rs702689, rs832582,
rs5868032, rs1799977,
rs1805794, rs1044009,
rs2228006, rs5744751,
rs1042522
29
14,930 na PALB2 NM_024675:
c.925A > G, p.I309V
(rs3809683)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1048108,
rs1799966, rs16942,
rs16941, rs799917,
rs4986850, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs12642536, rs702689,
rs832582, rs5868032,
rs1799977, rs3219489,
rs1805794, rs1044009,
rs152451, rs2228006,
rs1805321, rs5744934,
rs1042522
30
18,843 MSH6 NM_000179.2:
c.2195G > A, p.R732Q
(rs749746725)
BRCA1 NM_007300:
c.3119G > A,
p.S1040 N
(rs4986852)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs11528010,
rs144848, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs12642536, rs832582,
rs5868032, rs1799977,
rs3219489, rs1044009,
rs2228006, rs1805321,
rs5744934, rs5744751,
rs1042522, rs861539
26
19,411 na BARD1 NM_000465:
c.1972C > T, p.R658C
(rs3738888) PALB2
NM_024675: c.1010 T >
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1799966,
rs16942, rs16941,
rs799917, rs4986850,
28
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals (Continued)
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
C, p.L337S
(rs45494092)
rs144848, rs169547,
rs1805107, rs506504,
rs1126497, rs12642536,
rs702689, rs832582,
rs5868032, rs1805794,
1,044,009, rs2228006,
rs1805321, rs5744751,
rs1042522, rs861539
19,673 AXIN2 NM_004655:
c.344A > G, p.N115S
(rs370257532)
APC NM_001127510:
c.7504G > A, p.G2502S
(rs2229995) PMS2
NM_000535: c.1454C >
A, p.T485 K
(rs1805323)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1799966,
rs16942, rs16941,
rs799917, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs702689, rs832582,
rs5868032, rs1042821,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs4796033, rs1042522,
rs861539, rs3218536
29
20,612 na CDKN2A NM_000077:
c.442G > A, p.A148T
(rs3731249)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs11528010,
rs1799966, rs16942,
rs16941, rs799917,
rs169547, rs4986764,
rs1805107, rs506504,
rs12642536, rs702689,
rs5868032, rs1799977,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs10254120, rs5744934,
rs4796033, rs1042522,
rs861539
28
21,368 MAP3K1 NM_005921:
c.764A > G, p.N255S
(rs56069227)
ATM NM_000051:
c.2572 T > C, p.F858
L (rs1800056)
rs459552, rs659243,
rs2240308, rs2229571,
rs11528010, rs1799950,
rs169547, rs1805107,
rs506504, rs1126497,
rs702689, rs832582,
rs5868032, rs1799977,
rs1044009, rs2228006,
rs1805321, rs5744934,
rs4796033, rs1042522
22
22,295 na BRCA1 NM_007300:
c.5019G > A, p.M1673I
(rs1799967) BRIP1
NM_032043: c.890A >
G, p.K297R
(rs28997570)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1048108,
rs1799966, rs16942,
rs16941, rs799917,
rs144848, rs169547,
rs1805107, rs506504,
rs12642536, rs702689,
rs832582, rs5868032,
rs1799977, rs1042821,
rs3219489, rs1805794,
rs1044009, rs2228006,
rs1805321, rs5744934,
rs1042522, rs861539
30
23,761 na na rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs11528010,
rs1799966, rs16942,
26
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals (Continued)
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
rs16941, rs799917,
rs1799950, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs702689,
rs832582, rs5868032,
rs1799977, rs1044009,
rs2228006, rs1805321,
rs1802683, rs1042522
23,910 na BRCA2 NM_000059:
c.6100C > T, p.R2034C
(rs1799954) MSH2
NM_000251: c.965G >
A, p.G322D (rs4987188)
MSH6 NM_000179:
c.2633 T > C, p.V878A
(rs2020912) PALB2
NM_024675: c.2794G >
A, p.V932 M (rs45624036)
PMS2 NM_000535:
c.1454C > A, p.T485 K
(rs1805323) BARD1
NM_000465: c.1670G >
C, p.C557S (rs28997576)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs11528010,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs702689,
rs832582, rs5868032,
rs1799977, rs1042821,
rs1805794, rs2228006,
rs10254120, rs1042522,
rs13125836, rs3218536
28
24,140 na BRCA1 NM_007300:
c.5019G > A, p.M1673I
(rs1799967) PMS2
NM_000535: c.1531A >
G, p.T511A (rs2228007)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1048108,
rs1799966, rs16942,
rs16941, rs799917,
rs144848, rs169547,
rs1805107, rs506504,
rs1126497, rs702689,
rs832582, rs5868032,
rs1799977, rs1042821,
rs3219489, rs1805794,
rs1044009, rs2228006,
rs10254120, rs5744751,
rs1042522
29
24,447 CHEK2 NM_007194:
c.74 T > C, p.V25A
(rs587780188)
NOTCH3 NM_000435:
c.3399C > A, p.H1133Q
(rs112197217)
rs459552, rs659243,
rs1801516, rs2240308,
rs2070094, rs2229571,
rs1799966, rs16942,
rs16941, rs799917,
rs169547, rs1805107,
rs506504, rs1126497,
rs702689, rs832582,
rs5868032, rs1805794,
rs1044009, rs2228006,
rs1805321, rs1042522
24
11,705 ATM NM_000051:
c.4375G > A, p.G1459R
(rs145667735) MSH2 NM_000251:
c.1284C > G, p.H428Q
(rs776034412)
MSH2 NM_000251:
c.965G > A,
p.G322D (rs4987188)
PMS2 NM_000535:
c.1454C > A, p.T485
K (rs1805323)
rs459552, rs659243,
rs1801516, rs2229571,
rs11528010, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs702689, rs832582
rs5868032, rs1799977,
rs3219489, rs1805794,
rs1044009, rs2228006,
rs1805321, rs5744751,
rs1042522, rs861539,
rs13125836
27
12,673 na ATM NM_000051:
c.2572 T > C,
rs459552, rs659243,
rs2240308, rs2070094,
26
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals (Continued)
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
p.F858 L (rs1800056)
PMS2 NM_000535:
c.1454C > A, p.T485 K
(rs1805323)
rs2229571, rs1048108,
rs1799950, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs12642536, rs702689,
rs832582, rs5868032,
rs1799977, rs1044009,
rs2228006, rs1805321,
rs1802683, rs4796033,
rs1042522, rs861539
13,393 NBN NM_002485.4:
c.643C > T, p.R215W
(rs34767364)
BARD1 NM_000465:
c.1972C > T, p.R658C
(rs3738888) BRIP1
NM_032043: c.577G >
A, p.V193I (rs4988346)
PMS2 NM_000535:
c.1531A > G, p.T511A
(rs2228007) ATM
NM_000051: c.4258C >
T, p.L1420F (rs1800058)
NOTCH3 NM_000435.2:
c.3058G > C, p.A1020P
(rs35769976) NOTCH3
NM_000435: c.3547G >
A, p.V1183 M
(rs10408676)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1799966,
rs16942, rs16941,
rs799917, rs169547,
rs4986764, rs1805107,
rs506504, rs702689,
rs832582, rs5868032,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs1042522
28
14,963 PALB2 NM_024675:
c.232G > A, p.V78I
(rs515726085)
PALB2 NM_024675:
c.2590C > T,
p.P864S (rs45568339)
STK11 NM_000455:
c.1062C > G, p.F354 L
(rs59912467)
rs659243, rs1801516,
rs2240308, rs2070094,
rs2229571, rs11528010,
rs1799966, rs16942,
rs16941, rs799917,
rs1799950, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs12642536,
rs702689, rs5868032,
rs1799977, rs3219489,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs5744751, rs1042522,
rs861539, rs3218536
33
19,609a na BRCA2 NM_000059:
c.4258G > T, p.D1420Y
(rs28897727) POLE
NM_006231: c.2083
T > A, p.F695I
(rs5744799)
rs459552, rs659243,
rs2240308, rs2229571,
rs1799966, rs16942,
rs16941, rs799917,
rs144848, rs169547,
rs4986764, rs1805107,
rs506504, rs702689,
rs832582, rs5868032,
rs1799977, rs3219484,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs5744934, rs1042522,
rs13125836
28
22,953 NOTCH3 NM_000435:
c.5208G > C, p.E1736D
(rs200331646)
MSH2 NM_000251:
c.128A > G, p.Y43C
(rs17217723) RAD51B
NM_133510: c.515 T >
G, p.L172 W (rs34094401)
BRCA2 NM_000059:
c.2971A > G,
p.N991D (rs1799944)
CDH1
NM_004360: c.1774G >
A, p.A592T (rs35187787)
rs459552, rs659243,
rs2240308, rs2229571,
rs11528010, rs1799966,
rs16942, rs16941,
rs799917, rs169547,
rs4986764, rs1805107,
rs506504, rs12642536,
rs702689, rs832582,
rs5868032, rs1042821,
rs3219489, rs1805794,
29
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Table 2 Characterization of germline variants found among Norwegian familial CRC individuals (Continued)
Patient_
ID
VUS
(Class 3)
Benign or
Likely Benign
variants (Class 1 or 2)
Polymorphisms Total
variants/
patient
rs1044009, rs2228006,
rs1805321, rs1726801
24,789 APC NM_001127510:
c.4334C > T, p.T1445I
(rs760686348) PALB2
NM_024675: c.1250
C > A, p.S417Y
(rs45510998)
BARD1 NM_000465:
c.1972C > T,
p.R658C
(rs3738888) PALB2
NM_024675:
c.2993G > A,
p.G998E (rs45551636)
PALB2 NM_024675:
c.2014G > C,
p.E672Q (rs45532440)
POLE NM_006231:
c.776G > A, p.R259H
(rs61732929)
NOTCH3 NM_000435:
c.3399C >
A, p.H1133Q
(rs112197217)
rs459552, rs659243,
rs2240308, rs2229571,
rs1799966, rs16942,
rs16941, rs799917,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs12642536,
rs702689, rs832582,
rs5868032, rs1799977,
rs3219489, rs1044009,
rs152451, rs2228006,
rs1042522
30
25,167 NBN NM_
002485.4:
c.643C > T,
p.R215W
(rs34767364)
ATM NM_000051:
c.2119 T > C,
p.S707P
(rs4986761)
rs459552, rs659243,
rs2240308, rs2229571,
rs11528010, rs169547,
rs4986764, rs1805107,
rs506504, rs12642536,
rs702689, rs832582,
rs5868032, rs1799977,
rs1805794, rs2228006,
rs1805321, rs1726801,
rs4796033, rs1042522
22
5597 MAP3K1 NM_005921:
c.2816C > G, p.S939C
(rs45556841)
ATM NM_
000051:
c.5071A >
C, p.S1691R
(rs1800059)
rs459552, rs659243,
rs1801516, rs2070094,
rs2229571, rs11528010,
rs1799966, rs16942,
rs16941, rs799917,
rs4986850, rs144848,
rs169547, rs4986764,
rs1805107, rs506504,
rs1126497, rs12642536,
rs702689, rs832582,
rs5868032, rs1042821,
rs1805794, rs1044009,
rs2228006, rs1805321,
rs1042522
29
8913 RAD51B NM_133509:
c.1063G > A, p.A355T
(rs61758785) EPCAM
NM_002354:
c.267G > C, p.Q89H
(rs146480420)
PMS2 NM_000535:
c.1454C > A, p.T485
K (rs1805323)
rs459552, rs659243,
rs2240308, rs2070094,
rs2229571, rs1048108,
rs11528010, rs1799966,
rs16942, rs16941,
rs799917,
rs144848, rs169547,
rs4986764, rs1805107,
rs506504, rs1126497,
rs702689, rs832582,
rs5868032, rs1805794,
rs1044009, rs2228006,
rs5744751, rs1042522,
rs861539, rs13125836
30
a Recently classified as Benign by ACMG Guidelines, 2015
b Patient ID carrying CHEK2 c.470 T > C, p.I157T
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is reported in ClinVar as “conflicting interpretations of
pathogenicity, risk factor” (Variation ID: 5591). When
the revised Bethesda guidelines were considered, the
mutation detection rate was thus 4.8% (1/21).
Overall, 25 unique VUS were found in 18 out of the
34 patients (Table 2). The detected VUS were distributed
among 17 different genes: MAP3K1 (in 2 patients), NBN
(in 3 patients), NOTCH3 (in 3 patients), RAD51B (in 3
patients), MSH2 (in 2 patients), PALB2 (in 2 patients),
POLE (in 2 patients) and the remaining were found in
APC, ATM, AXIN2, BRCA1, CHEK2, EPCAM, MSH6,
MUTYH, RAD51C and STK11 (Table 2). The minor al-
lele frequency (MAF) values of these variants were very
low or no frequency data have been reported.
Protein and splicing-dedicated in silico analyses
The 25 unique VUS were analyzed by using five in silico
prediction tools with different underlying algorithms to
estimate the impact of the variants on the structure and
function of the corresponding proteins.
Concordances between the 5 prediction tools were
found for 2 out of the 25 VUS, suggesting a potentially
damaging effect on protein level for the variants:
MUTYH c.812G > A (p.R271Q) and MSH2 c.128A > G
(p.Y43C) (Table 3). In the other hand, 6 out of 25 VUS
were consistently predicted as benign: NBN c.1720 T > A
(p.L574I),
BRCA1 c.4315C > T (p.L1439F), MAP3K1 c.764A > G
(p.N255S), CHEK2 c.74 T > C (p.V25A), PALB2
c.232G > A (p.V78I) and APC c.4334C > T (p.T1445I).
Discrepancies were pronounced for the variants in the
POLE (n = 2), STK11, MAP3K1, PSMC3IP, RAD51C,
MSH6, AXIN2, MSH2, NBN, NOTCH3, RAD51B, PALB2
and EPCAM genes (Table 3).
Two out of the 25 VUS were bioinformatically pre-
dicted to affect RNA maturation by potentially modify-
ing splicing signals (Table 3). More specifically,
according to our in silico results, NOTCH3 c.5854G >A
(identified in Patients 3222 and 4932) was predicted to
potentially induce exon 32 skipping by alteration of ex-
onic splicing regulatory elements, whereas MAP3K1
c.764A > G (detected in Patient 21,368) was predicted to
introduce a deletion of the first 131 nucleotides of exon
3 (r.634_764del) due to the creation of a putative new
acceptor splice site. Skipping of NOTCH3 exon 32
would produce a transcript with a frameshift deletion of
98 nucleotides (NOTCH3 r.5816_5913del), potentially
leading to the production of a carboxy-terminally trun-
cated NOTCH3 protein p.(Lys1940Glyfs*14). The
MAP3K1 r.634_764del transcript would be expected to
be degraded by nonsense mediated decay and/or result
in a very short MAP3K1 protein p.(Val212Leufs*45).
The NOTCH3 c.5854G >A was identified in two patients
(Patients 3222 and 4932) that fulfilled the revised
Bethesda guidelines and AMS criteria, respectively while
the MAP3K1 c.764A > G (Patient 21,368) in a patient
which family fulfilled the revised Bethesda guidelines
(Table 1).
Minigene splicing assays
Because patient RNA was not available, we decided to
experimentally assess the impact of these 2 variants
(NOTCH3 c.5854G >A and MAP3K1 c.764A > G) might
have on RNA splicing by performing cell-based mini-
gene splicing assays.
As shown in Fig. 1 we found that NOTCH3
c.5854G >A and MAP3K1 c.764A > G did not modify the
splicing pattern of the minigenes’ transcripts. These data
thus disagree with the in silico predictions and suggest
that either the exon 32 of NOTCH3 and the exon 3 of
MAP3K1 are refractory to splicing mutations (the pre-
dictions thus being incorrect) or that the minigenes used
in our study do not fully reproduce the splicing pattern
of the mutant exons in NOTCH3 and MAP3K1 bona
fide transcripts (the predictions being eventually cor-
rect). Complementary studies using RNA from NOTCH3
c.5854G >A and MAP3K1 c.764A > G carriers need to be
performed to verify the pertinence of these results.
Discussion
The major unexpected finding in our Norwegian high-
risk CRC cohort was the detection of a likely pathogenic
variant in CHEK2 (c.470 T > C, p.I157T), a moderate-
penetrance gene not traditionally associated with CRC,
in an individual with a LS-evocative personal/family his-
tory and a high number of Class 3 variants in BC- and
CRC- associated genes. Interestingly, the CHEK2
(c.470 T > C, p.I157T) has an allele frequency of
1.89*10–3 in the Norwegian population (http://norgen-
e.no/vcf-miner/), and is reported in ClinVar as having
conflicting interpretations of pathogenicity/being a risk
factor (Variation ID: 5591). Importantly, there is no sys-
tematic classification for most of the genetic variants
found by NGS, and, in more general terms, the impact
of low- to moderate-penetrance pathogenic variants with
respect to clinical management is not fully understood
[52]. Co-segregation or case-control studies for further
evaluation will be key in understanding whether such
germline variant may have a modifying effect, since we
do not yet have evidence-based guidelines for the major-
ity of these genes.
On the other hand, CHEK2 germline variants have
been described to confer an elevated risk of BC (relative
risk = 3.0) [53]. However, the presence of pathogenic var-
iants in CHEK2 is not frequently associated with cancer
in high-risk BC families, prompting speculation that
there may be several low-penetrance or moderate-
penetrance BC risk genes segregating independently
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within these families [23, 54, 55]. Co-segregation ana-
lyses may add clues in our understanding whether this
germline variant is implicated in CRC predisposition. Fi-
nally, we did not find pathogenic variants in POLE in
our cohort, which is in contrast to what has been de-
scribed in families with high burden of CRC adenomas
and carcinomas in addition to extra-colonic cancers
[56].
According to the Prospective LS Database (PLSDB), a
total of 125 Norwegian families had a demonstrated
pathogenic variant in either MLH1 (n = 21), MSH2 (n =
52), MSH6 (n = 36), or PMS2 (n = 16) [25]. On the other
hand, a large portion of high-risk CRC families without
pathogenic variant in MMR or EPCAM genes may be
explained by a polygenic model involving a combination
of multiple genomic risk factors, including the effect of
either low-penetrance susceptibility alleles [57], high-
penetrance genes which have not been tested, or the ef-
fect of environmental factors. In addition, emerging data
suggest that CRC cases negative for pathogenic MMR
variants may contain a significantly higher number of
copy-neutral loss of heterozygosity (cnLOH) regions,
some located within well-known oncogenes and tumor
suppressor genes, compared to cases of sporadic CRC
[58]. These genomic variations, which were not investi-
gated in this study, may provide an additional explan-
ation for high-risk CRC phenotypes without MMR or
EPCAM pathogenic variants.
Recent NGS studies described the presence of hetero-
zygous pathogenic BRCA1/2 or APC variants as well as
biallelic MUTYH alterations in individuals with clinical
features resembling those of LS [5, 22]. More precisely,
those studies reported that 7% of patients with CRC car-
ried pathogenic variants in non-LS genes, including 1.0%
with BRCA1/2 mutations, and nearly two thirds of pro-
bands with high-penetrance non-LS mutations lacked
clinical histories suggestive of their respective syndromes
[5].
From 34 high-risk CRC individuals, our NGS panel
testing identified one patient that carried a pathogenic
variant in a gene with reportedly moderate penetrance.
Our finding is in line with the mutation frequency (6%)
in non-LS cancer susceptibility genes for individuals
undergoing LS genetic testing [21] and 4% of patients
with BC tested negative for BRCA1/2 genes [23]. Our re-
sults may have implications for an appropriate genetic
a d
b
c
Fig. 1 Evaluation of variant-induced splicing alterations by using a cell-based minigene assay. a Structure of pCAS2 minigenes used in the splicing reporter
assay. The bent arrow indicates the CMV promoter, boxes represent exons, lines in between the boxes indicate introns, and arrows below the exons
represent primers used in RT-PCR reactions. The minigenes were generated by inserting a genomic fragment containing the exon of interest together with
its flanking intronic sequences into the intron of pCAS2, as described under Materials and Methods. b Analysis of the splicing pattern of pCAS2 minigenes
carrying variants identified in this study. Wild-type (WT) and mutant constructs, as indicated, were introduced into HeLa cells and the transcripts of the
minigenes were analyzed by RT-PCR 24 h post-transfection. The image shows the results of a representative experiment in which the RT-PCR products
were separated on a 2.5% agarose gel stained with EtBr and visualized by exposure to ultraviolet light. M, 100 bp DNA ladder (New England Biolabs). c
Quantification of splicing events observed in the minigene splicing assay. The relative levels of exon inclusion indicated under the gel are based on RT-
PCR experiments equivalent to those shown in B but performed with a fluorescent forward primer and then separated on an automated sequencer.
Quantification results were obtained by using the GeneMapper v5.0 software (Applied Biosystems) and correspond to the average of two independent
fluorescent-RT-PCR experiments. d Representative fluorescent RT-PCR experiment. The panel shows superposed peaks corresponding to the WT and
mutant products (in blue and red, respectively), as indicated
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counseling and follow-up of the patients and family
members.
Besides the likely pathogenic CHEK2 variant, we iden-
tified a total of 25 variants in our cohort for which there
were not so much data as to their clinical significance.
We thus undertook bioinformatics analyses in an at-
tempt to predict the biological impact of these Class 3
variants, both at the RNA and protein level, the ultimate
goals being: (i) to discriminate pathogenic from non-
pathogenic alterations in this set of variants and (ii) to
further pinpoint the genetic determinants of high risk
CRC in our cohort. On one hand, our RNA splicing-
dedicated bioinformatics evaluation predicted that 2 out
of the 25 VUS identified in this study (NOTCH3
c.5854G >A, p.V1952 M and MAP3K1 c.764A > G,
p.N255S) could potentially affect RNA splicing. These
two variants were then experimentally analyzed by per-
forming minigene splicing assay. Our results revealed
that neither variant altered the splicing pattern of the
representative minigenes, suggesting that they do not
affect the splicing of NOTCH3 or MAP3K1 transcripts.
Additional experiments based on the analysis of RNA
from carriers of these variants will be important to verify
our minigene results. On the other hand, our protein-
dedicated bioinformatics analysis yielded 8 consistent
predictions (2 VUS predicted as deleterious and 6 as be-
nign) and several conflicting results that were not ex-
plored further.
In this scenario, not only functional tests, but also
co-segregation studies will be key to understanding
whether the VUS detected in this work are non-
pathogenic or otherwise have a causal or a modifying
effect. Importantly, we do not yet have evidence-
based guidelines for the majority of the genes carry-
ing the VUS identified in this study and, in more gen-
eral terms, the impact of low- to moderate-
penetrance pathogenic variants with respect to clinical
management is not fully understood. Most of these
variants may in the future be reclassified as deleteri-
ous or benign, but in the meantime, they cannot be
used to make clinical decisions [59]. Informed (re)-
classification of VUS in cancer-associated genes may
cater to more appropriate risk-management, and may
provide significant clues for the identification of add-
itional patients carrying such uncommon variants.
NGS panel testing may benefit patients with a personal
or family history compatible with more than one recog-
nized CRC inherited syndrome. The CRC risk manage-
ment strategy for these individuals is not yet available
and there is a need to identify new high-, moderate-,
and low- penetrance gene variants that may affect the
risk of CRC or LS-associated tumors in non-MMR
pathogenic carriers. The identification of such gene vari-
ants in combination with family history may contribute
to more intensive surveillance and improved prevention
[23].
Conclusions
Our study provides information on genetic locus that
might possibly be related to cancer susceptibility, dem-
onstrating that genes presently not routinely tested may
be important for capturing cancer predisposition in
these patients. In addition, we stratified 25 VUS by the
use of RNA splicing- and protein-dedicated in silico ana-
lyses. Further studies are necessary for making reliable
estimates of cancer risk for the VUS found in this study
and allowing appropriate genetic counseling for the pa-
tients and their relatives.
Surveillance for early cancer detection is essential to
ensure optimal survival for patients afflicted with famil-
ial cancers. Our findings pinpoint the need of more
studies to unravel the mechanisms underlying the devel-
opment of CRC in high-risk patients and the identifying
for new cancer predisposition genes.
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